Invention Grant
- Patent Title: Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
-
Application No.: US13196724Application Date: 2011-08-02
-
Publication No.: US08999324B2Publication Date: 2015-04-07
- Inventor: Pablo Umaña , Joël Jean-Mairet , James E. Bailey
- Applicant: Pablo Umaña , Joël Jean-Mairet
- Applicant Address: DE Switzerland
- Assignee: Roche GlycArt AG
- Current Assignee: Roche GlycArt AG
- Current Assignee Address: DE Switzerland
- Agency: Sterne, Kessler, Goldstein & Fox PLLC
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C12P21/08 ; C12N9/10 ; C07K16/00 ; C07K16/28 ; C07K16/30 ; C12P21/00 ; A61K39/00
Abstract:
The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.
Public/Granted literature
- US20110293609A1 Antibody Glycosylation Variants Having Increased Antibody-Dependent Cellular Cytotoxicity Public/Granted day:2011-12-01
Information query
